EZH2 and cancer: New classes of agents targeting androgen receptor signalling, poly (ADP-ribose) polymerase (PARP), enhancer of zeste homolog 2 (EZH2), cyclin-dependent kinases 4 and 6 (CDK4/6), and immunotherapies are being explored in cancer.